{"id":"vorapaxar-aspirin-and-clopidogrel","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Bleeding"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"3-8","effect":"Bruising"},{"rate":"2-5","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vorapaxar is a PAR-1 antagonist that prevents thrombin-induced platelet activation. Aspirin irreversibly inhibits cyclooxygenase and reduces thromboxane A2 production. Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-induced platelet aggregation. Together, these three agents provide complementary antiplatelet effects to reduce thrombotic events.","oneSentence":"This combination therapy inhibits platelet aggregation through multiple pathways: vorapaxar blocks the protease-activated receptor-1 (PAR-1), while aspirin and clopidogrel inhibit different steps in platelet activation and clotting cascade.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:15:52.889Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Secondary prevention of cardiovascular events in patients with stable coronary artery disease or peripheral artery disease"}]},"trialDetails":[{"nctId":"NCT03207451","phase":"PHASE4","title":"Vorapaxar on Thrombin Generation and Coagulability","status":"COMPLETED","sponsor":"Inova Health Care Services","startDate":"2016-01-01","conditions":"Coronary Artery Disease, Peripheral Vascular Disease, Myocardial Infarction","enrollment":81},{"nctId":"NCT02548650","phase":"PHASE4","title":"Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-03-25","conditions":"Myocardial Infarction, Diabetes Mellitus, Peripheral Arterial Disease","enrollment":66},{"nctId":"NCT00684203","phase":"PHASE2","title":"Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-01","conditions":"Atherosclerosis, Myocardial Ischemia, Myocardial Infarction","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Group 4"],"phase":"marketed","status":"active","brandName":"Vorapaxar, Aspirin, and Clopidogrel","genericName":"Vorapaxar, Aspirin, and Clopidogrel","companyName":"Inova Health Care Services","companyId":"inova-health-care-services","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy inhibits platelet aggregation through multiple pathways: vorapaxar blocks the protease-activated receptor-1 (PAR-1), while aspirin and clopidogrel inhibit different steps in platelet activation and clotting cascade. Used for Acute coronary syndrome, Secondary prevention of cardiovascular events in patients with stable coronary artery disease or peripheral artery disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}